CST: 29/09/2016 23:55:09   

Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care

233 Days ago

TORONTO, CANADA--(Marketwired - Feb 9, 2016) - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (FRANKFURT:FME)(NYSE:FMS), the worlds' largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).

In July 2010, IBI announced the signing of a definitive license and supply agreement whereby Fresenius Medical Care was offered an exclusive worldwide license to apply IBI's EndexoTM technology to various components - including dialyzers and blood lines - of their chronic dialysis circuits for treating patients with end stage renal disease. This agreement has now been extended to include the acute dialysis market.

EndexoTM is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, thereby potentially reducing the use of drugs such as heparin. As an additive, Endexo™ has significant manufacturing advantages over other anti-thrombogenic coating or impregnation technologies and does not change the mechanical or functional properties of the underlying medical device.

"We continue to be encouraged by the results we've seen with the Endexo modified products. We look forward to working with Interface Biologics to finalize our testing, pursue regulatory approval and ultimately commercialize Endexo enhanced products from Fresenius Medical Care now for both the chronic and acute dialysis markets." commented Mark Costanzo, President of the Renal Therapies Group at Fresenius Medical Care.

"This extension of our licensing agreement with Fresenius Medical Care to include the acute dialysis market is further testament to the benefits of our Endexo surface modification technology," commented Tom Reeves, President and CEO of Interface Biologics. "Acute dialysis is a critical therapy for many very ill patients and we believe that the Endexo additives will further improve the safety and effectiveness of these devices. The extension of our licensing agreement also underscores the continued progress that Fresenius has made in using the Endexo additives in their chronic dialysis circuits used in treating end stage renal disease."

About Interface Biologics, Inc.

Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic devices that reduce thrombosis, anti-infective polymers, and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com

About Fresenius Medical Care

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,402 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 290,250 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.

For more information visit the Company's website at www.freseniusmedicalcare.com.

Julie Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca
416-951-7988